Fagron N.V. Logo

Fagron N.V.

A global pharmaceutical compounding company focused on personalized medicine.

FAGR | BR

Overview

Corporate Details

ISIN(s):
BE0003874915
LEI:
549300TRKRUFK2RRG779
Country:
Belgium
Address:
Venecoweg 20A, 9810 Nazareth

Description

Fagron N.V. is a global company active in pharmaceutical compounding, focusing on the delivery of personalized medicine. The company optimizes and innovates compounding to widen the therapeutic options for prescribers worldwide. Fagron develops, markets, and distributes pharmaceutical raw materials, equipment, and specially formulated vehicles and bases, such as the Pentravan® transdermal base and the SyrSpend® range of oral suspending vehicles. Its primary customers are hospitals, pharmacies, and clinics. The company also operates in the field of genomics to further support personalized healthcare solutions.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-12-19 07:49
Fagron accelerates global expansion with two strategic acquisitions and a key N…
Dutch 184.1 KB
2025-12-19 07:49
Fagron accelerates global expansion with two strategic acquisitions and a key N…
English 167.2 KB
2025-12-19 07:00
Fagron accelerates global expansion with two strategic acquisitions and a key N…
English 167.2 KB
2025-12-19 07:00
Fagron versnelt globale expansie met twee strategische overnames en verkrijgt b…
Dutch 184.1 KB
2025-11-24 07:30
Fagron strengthens EMEA leadership with acquisitions in Poland and Hungary and …
Dutch 207.9 KB
2025-11-24 07:30
Fagron strengthens EMEA leadership with acquisitions in Poland and Hungary and …
English 180.2 KB
2025-11-24 07:00
Fagron strengthens EMEA leadership with acquisitions in Poland and Hungary and …
English 180.2 KB
2025-11-24 07:00
Fagron versterkt leiderschap in de EMEA-regio met overnames en kondigt belangri…
Dutch 207.9 KB
2025-11-17 07:43
Fagron completes share buy-back program
Dutch 157.2 KB
2025-11-17 07:43
Fagron completes share buy-back program
English 154.6 KB
2025-11-14 18:00
141125_Press release progress share buy back program Fagron - ENG.pdf
English 154.6 KB
2025-11-14 18:00
141125_Press release progress share buy back program Fagron - NL.pdf
Dutch 157.2 KB
2025-11-10 07:34
Fagron’s share buy-back program: Weekly update
English 156.1 KB
2025-11-10 07:34
Fagron’s share buy-back program: Weekly update
Dutch 157.8 KB
2025-11-07 18:00
071125_Press release progress share buy back program Fagron - ENG.pdf
English 156.1 KB

Automate Your Workflow. Get a real-time feed of all Fagron N.V. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Fagron N.V.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Fagron N.V. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2023-12-05 AOC Pharma S.à r.l. Close relation Buy 175,000 3,001,250.00 EUR
2023-10-20 AOC Pharma S.à r.l. Close relation Buy 500 7,748.65 EUR
2023-10-19 De Jong Cornelia Neeltje Board Buy 2,500 38,750.00 EUR
2022-08-04 Padilla Rafael Board Buy 3,500 49,945.00 EUR
2021-12-03 De Jong Cornelia Neeltje Board Buy 2,000 27,280.00 EUR
2021-12-02 De Jong Cornelia Neeltje Board Buy 2,500 33,250.00 EUR
2021-12-01 Van Rietschoten Constantijn Executive member Buy 2,500 33,375.00 EUR
2021-11-30 Verlinden Johan Executive member Buy 5,000 66,199.70 EUR
2021-11-30 Padilla Rafael Board Buy 3,710 49,899.50 EUR
2021-11-29 Van Rietschoten Constantijn Executive member Buy 9,500 127,449.83 EUR

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.